Today, Blackstone announced that one of its affiliated private equity entities based in Mauritius had entered into an agreement to sell its equity stake in Pune-based Emcure Pharmaceuticals Limited to Bain Capital. Emcure is engaged in developing, manufacturing and marketing a well-diversified range of pharmaceutical products globally. In addition to providing growth capital to expand our business multi-fold, they also shared strategic insights to manage our fast growing business effectively. We are delighted that we have lived up to the faith reposed in us by Blackstone.
|Published (Last):||9 February 2017|
|PDF File Size:||9.80 Mb|
|ePub File Size:||18.84 Mb|
|Price:||Free* [*Free Regsitration Required]|
The issue also involves a secondary sale 2. Blackstone has invested Rs crore in Emcure through convertible shares and currently holds a The PE firm is selling around 1.
Book running lead managers to the issue include Bank of America Merrill Lynch. Another pharmaceutical firm which filed for public offering recently was Intas Pharmaceuticals. Emcure is ranked as the 14th-largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products.
It is ranked as the 7th-largest pharmaceutical company in the therapeutic areas in which it operates. These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients.
In April , Emcure acquired Heritage Pharmaceuticals, a New Jersey-based generic pharmaceutical company, which provided it a commercial platform to market and sell its products. Of these revenues, All rights reserved. The content may not be copied, broadcast, downloaded and stored in any medium , transmitted, adapted or changed in any way whatsoever without the prior written permission of Mosaic Media Ventures Private Limited.
Emcure Pharmaceuticals files for IPO; Blackstone to part exit
The issue also involves a secondary sale 2. Blackstone has invested Rs crore in Emcure through convertible shares and currently holds a The PE firm is selling around 1. Book running lead managers to the issue include Bank of America Merrill Lynch.
EMCURE PHARMACEUTICALS LTD
The Issue comprises a fresh issue of Equity Shares aggregating up to Rs. The Company is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Its core strength lies in in-house development and manufacturing of differentiated pharmaceutical products. The Company focuses its research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules, biosimilars and novel drug delivery systems. The Company commercializes its products through a combination of its own marketing and distribution infrastructure across geographies as well as relationships with multi-national pharmaceutical companies. The Company believes its competitive advantage in the domestic market lies in its established presence in all major therapeutic areas.
Tegore Emcure was the first private equity investment by a Blackstone-managed fund in India. For the nine months period ended December Reproduction of news articles, photos, videos or any other content in whole or drnp part in any form or medium without express writtern permission of moneycontrol. Book running lead managers to the issue include Bank of America Merrill Lynch. Emcurw areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients.